Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).
Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).
In a 5-year study reported in the Journal of Glaucoma, 36 previously untreated POAG patients received topical travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories), once in the evening in both eyes.
All patients received a pre-treatment 24-hour IOP evaluation, followed by a series of 5 follow-up 24-hour evaluations at 12-month intervals throughout the trial.
In the 34 patients who completed the study, the travoprost monotherapy reduced the mean 24-hour IOP from 23.4 (±1.7) mmHg at baseline to the following:
To read an abstract of the study, click here.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.